<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441597</url>
  </required_header>
  <id_info>
    <org_study_id>atorv01</org_study_id>
    <nct_id>NCT00441597</nct_id>
  </id_info>
  <brief_title>Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?</brief_title>
  <official_title>Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after
      ischemic exercise in the non-dominant forearm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) have been
      found to reduce cardiovascular events. This protective effect has been traditionally
      explained by lowering plasma cholesterol and subsequent reduced progression of
      atherosclerosis. However in animal experiments statins have also shown the ability to induce
      pharmacologic preconditioning and thereby reduce infarct size. This effect contributes to the
      beneficial effect of statins on reducing of cardiovascular events. In order to differentiate
      between these two mechanisms of protection we will study the effect of atorvastatin on
      ischemia reperfusion damage after a short exposure to atorvastatin, before the lipid lowering
      effect of atorvastatin becomes apparent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annexin A 5 targeting in the non dominant thenar muscle after ischemic exercise, as a indicator for ischemia reperfusion injury.</measure>
    <time_frame>60 and 240 minutes after ischemic exercise</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>workload during ischemic exercise</measure>
    <time_frame>workload during 10minutes of ischemic exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of 3-day treatment with atorvastatin 80mg daily on serum lipid levels</measure>
    <time_frame>fasting lipid levels before and at first day after 3 day treatment with atorvastatin</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>3 days treatment with placebo twice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatine 80mg, during 3 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age 18-50 years

          -  Informed consent

          -  Physical able to perform ischemic exercise

        Exclusion Criteria:

          -  History of any cardiovascular disease

          -  Hypertension (in supine position: systole &gt; 140 mmHg, diastole &gt; 90 mmHg)

          -  Diabetes mellitus (fasting glucose &gt; 7.0 mmol/L or random glucose &gt; 11.0 mmol/L)

          -  Hyperlipidaemia (fasting total cholesterol &gt; 5.5 mmol/l)

          -  Alanine-Amino-Transferase (ALAT) &gt;90 U/L

          -  Creatinine Kinase (CK) &gt;440 U/L

          -  Drug or alcohol abuse

          -  Concommitant chronic use of medication

          -  Administration of radioactivity in research setting during the last 5 years

          -  Participation to any drug-investigation during the previous 60 days as checked with
             VIP check according to CRCN standard procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RUMCN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.</citation>
    <PMID>15623546</PMID>
  </reference>
  <reference>
    <citation>Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterisation to clinical application--part II. Neth J Med. 2004 Dec;62(11):409-23. Review.</citation>
    <PMID>15685892</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <last_update_submitted>March 16, 2009</last_update_submitted>
  <last_update_submitted_qc>March 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>G Rongen</name_title>
    <organization>dept Pharmacology Toxicology UMCN</organization>
  </responsible_party>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>atorvastatine</keyword>
  <keyword>preconditioning</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

